More than 75 percent of ovarian cancer cases remain undiagnosed until the disease has reached an advanced stage.
A recent clinical trial conducted at nearly 200 sites around the world, including NYU Langone’s Perlmutter Cancer Center, showed that niraparib, a type of drug known as a poly ADP ribose polymerase (PARP) inhibitor, reduced disease progression 57 percent, and the time to disease progression was prolonged 12 months. Bhavana Pothuri, MD, professor in the Department of Obstetrics and Gynecology and a co-investigator of the study, discusses the results on WCBS Newsradio 880.
“The study results move PARP inhibitors for all patients into the front line after platinum-based chemotherapy and really should be considered a new standard of care,” Dr. Pothuri says.
Listen to Dr. Pothuri’s full interview on WCBS Newsradio 880.